Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V-212 Vaccine in Healthy Adults
NCT06975319Phase 1Completed
- Sponsor
- Virometix
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V-212 in pneumococcal disease (3 cohorts), sponsored by Virometix. Primary endpoints: Adverse Events at month 12, Solicited local and systemic adverse events and 3 more. Started Jan 2025; status: completed.
02
Drugs
V-212
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06975319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975319.